!!!EDITAS_11_8_2015_EMEA

Editas Medicine raised $120M for advance genome editing

August 11, 2015 • DEALS

Editas Medicine, a leading genome editing company, raised $120 million in a highly oversubscribed Series B private financing. It is noted that Editas is translating the promise of CRISPR/Cas9 technology into a new class of transformative genomic medicines to treat a broad range of diseases by enabling precise and corrective molecular modifications to treat disease at the genetic level.

Investors include Flagship Ventures, Polaris Partners, Third Rock Ventures, Partners Innovation Fund, Deerfield Management, Viking Global Investors, Fidelity Management & Research Company, funds and accounts managed by T. Rowe Price Associates, Inc., Google Ventures, Jennison Associates on behalf of certain clients, Khosla Ventures, EcoR1 Capital, Casdin Capital, Omega Funds, Cowen Private Investments and Alexandria Venture Investments. “With the new capital, we have a strong foundation from which we can broadly develop our genome editing platform and advance multiple new therapies toward clinical trials”, said Katrine Bosley, CEO of Editas Medicine.

Tags

Alexandria Venture Investments, Casdin Capital, Cowen Private Investments, Deerfield Management, EcoR1 Capital, Editas Medicine, Fidelity Management & Research Company, Flagship Ventures, Google Ventures, Inc., Jennison Associates, Katrine Bosley, Khosla Ventures, Omega Funds, Partners Innovation Fund, Polaris Partners, T. Rowe Price Associates, Third Rock Ventures, Viking Global Investors
Pin It

Related Posts